熱門資訊> 正文
Definium Therapeutics推出5亿美元公开募股
2026-06-23 04:08
- Definium Therapeutics (DFTX) announced plans for an underwritten public offering of $500M of common shares and, for certain investors, pre-funded warrants.
- Definium also intends to grant underwriters a 30-day option to purchase up to an additional $75M of common shares.
- All securities in the offering will be issued and sold by the company.
- Net proceeds will primarily fund research and development activities for Definium’s pipeline of psychiatric and neurological disorder treatments.
- Funds will also support commercialization preparation efforts for DT120 ODT, if the product receives regulatory approval.
- Remaining proceeds are expected to be used for working capital and other general corporate purposes.
More on Mind Medicine
- Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript
- Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential
- Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
- These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations
- Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit
推薦文章
華盛早報 | 美光盤后飆升近16%！炸裂財報引爆芯片股，納指期貨應聲漲2%；黃仁勛豪言AI進入盈利時代；高通全面進軍AI數據中心
美股前瞻 | AI風向標來襲！英偉達股東大會凌晨開始、美光財報盤后發佈；布油跌破75美元創戰后新低；海力士或7月10日登陸美股
SK海力士據報將向韓國監管機構提交文件 推進美國ADR上市計劃
中信證券港股策略：關注高解禁比例標的及行業龍頭解禁對股價的短期擾動
谷歌一夜蒸發15000億，只因失去了兩個人
SpaceX通過債市募資250億美元 認購需求顯示市場心態謹慎
拋售SpaceX，買入特斯拉？
資金覆盤 | 北水逆勢抄底港股近104億港元！加倉中芯國際、建滔集團，拋售阿里巴巴
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
